THOUSAND OAKS, Calif., Jan. 6, 2026 — Amgen announced the acquisition of Dark Blue Therapeutics Ltd., a privately held U.K. biotechnology company, in a transaction valued at up to $840 million.
The acquisition adds to Amgen’s pipeline an investigational small molecule designed to target and degrade the proteins MLLT1 and MLLT3, which drive certain forms of acute myeloid leukemia (AML). Preclinical leukemia models show promising anti-cancer activity and a mechanism distinct from currently available therapies, supporting investigation as a single agent and in combination to address treatment resistance and improve remission durability.
“Acute myeloid leukemia remains one of the most difficult cancers to treat, and we see an urgent need for new mechanisms capable of changing the trajectory of this disease,” said Jay Bradner, M.D., executive vice president of Research and Development at Amgen. “This acquisition complements and extends our research in targeted protein degradation and leukemia therapeutics and will help advance MLLT1/3-targeting medicines to clinical investigation.”
Amgen plans to integrate Dark Blue Therapeutics into its existing research organization to strengthen early oncology discovery efforts.
About Amgen
Amgen discovers, develops, manufactures and delivers medicines for serious illnesses. The company advances a broad pipeline across oncology, cardiovascular disease, bone health, inflammation and rare diseases, and applies human genetic data and technology to drug discovery and development. Amgen is a component of the Dow Jones Industrial Average and the Nasdaq-100 Index.
This release contains forward-looking statements that are subject to risks and uncertainties. For a discussion of factors that could cause actual results to differ materially from those expressed or implied, see Amgen’s filings with the U.S. Securities and Exchange Commission.
Media: Elissa Snook, 609-251-1407
Investors: Casey Capparelli, 805-447-1746
More information: Amgen.com and Amgen on social media.
Leave a Reply